Use of the thyroid 99Tcm scintiscan with lead-shield on the hot nodule in the diagnosis of autonomous adenoma

1987 ◽  
Vol 8 (4) ◽  
pp. 217-220 ◽  
Author(s):  
G. RIZZI ◽  
G. ARGIRÓ ◽  
L. GENTILE ◽  
G. CASTELLANO ◽  
C. BROSSA ◽  
...  
Keyword(s):  
Hot Nodule ◽  
Lead Shield ◽  
Autonomous Adenoma

scholarly journals Mortality from thyroid cancer in patients with hyperthyroidism: the Theagenion Cancer Hospital experience

2008 ◽  
Vol 159 (6) ◽  
pp. 799-803 ◽  
Author(s):  
Kalliopi Pazaitou-Panayiotou ◽  
Petros Perros ◽  
Maria Boudina ◽  
George Siardos ◽  
Apostolos Drimonitis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Previous History ◽  
Distant Metastases ◽  
Northern Greece ◽  
Hot Nodule ◽  
Increased Risk ◽  
History Of ◽  
The Relationship ◽  
Diagnosis Of Thyroid Cancer ◽  
Autonomous Adenoma

BackgroundThyroid carcinoma has been reported in patients operated for different types of hyperthyroidism and the probability of a hot nodule being malignant seems to be low. The aim of the present study was to explore the relationship between thyroid cancer, hyperthyroidism and outcome in a large cohort of patients who presented to a tertiary cancer centre in Northern Greece.PatientsAmong 720 patients treated for thyroid cancer, 60 had a concomitant diagnosis of hyperthyroidism due to Graves' disease (n=14), solitary autonomous adenoma (n=17), or multinodular goiter (n=29). Adverse prognostic factors were common in patients with a previous history of hyperthyroidism at the time of diagnosis of thyroid cancer, including cases where the cancer was discovered coincidentally after thyroid surgery for hyperthyroidism and cases where tumor size was more than 10 mm.ResultsIn 10 out of 17 patients with hyperthyroidism due to solitary autonomous adenomas, the tumor was located within the hot nodule and two of these patients developed local and distant metastases and died from the disease 4 and 15 years after thyroidectomy.ConclusionClinicians managing patients with hyperthyroidism need to be aware of the possible increased risk of thyroid cancer in this patient group.

Ultrasonic Evaluation of "Silent Regions" in the Thyroid Scintiscan

1978 ◽  
Vol 17 (01) ◽  
pp. 16-23 ◽  
Author(s):  
Ch. L. Zollikofer ◽  
J. Wewerka ◽  
Th. Frank
Keyword(s):  
Needle Biopsy ◽  
Clinical Course ◽  
Stimulation Test ◽  
Evaluation Procedure ◽  
Sonographic Diagnosis ◽  
Non Invasive ◽  
Evaluation Procedures ◽  
Ultrasonic Evaluation ◽  
Invasive Evaluation ◽  
Autonomous Adenoma

35 patients with scintigraphically silent thyroid regions without palpable cold nodules were further evaluated by ultrasonography. In 33 cases the sonographic diagnosis was confirmed by other examinations or the clinical course. 2 cases were misinterpreted right at the beginning of our series.The use of ultrasonography in evaluating silent thyroid regions in the totally decompensated autonomous adenoma, in unilateral thyroid aplasia, thyroiditis and hyperthyroidism is shown to be a reliable and valuable supplement to the clinical and radioisotopic evaluation procedures. When differentiating the totally decompensated autonomous adenoma from unilateral thyroid aplasia a stimulation test need not be performed in most cases. Suspected thyroiditis can be confirmed in a simple way. Being a non-invasive evaluation procedure, ultrasonography should be used before performing a needle biopsy.

Hot nodule in pyramidal lobe of Thyroid gland: a case report

2017 ◽  
pp. 19-23
Author(s):  
Muhammad Iqbal ◽  
Muhammad Naeem ◽  
Muhammad Imran ◽  
Muhammad Akhtar
Keyword(s):  
Case Report ◽  
Thyroid Gland ◽  
Hot Nodule ◽  
Pyramidal Lobe

scholarly journals University of Kiel Radiocarbon Measurements II

Radiocarbon ◽  
1967 ◽  
Vol 9 ◽  
pp. 257-260
Author(s):  
H. Willkomm ◽  
H. Erlenkeuser
Keyword(s):  
Proportional Counter ◽  
Atmospheric Pressure ◽  
Statistical Error ◽  
Quartz Tube ◽  
Sensitive Volume ◽  
Concrete Wall ◽  
Lead Shield ◽  
Double Ring

Most of the measurements reported here have been obtained with the 4.5-L CO2 counter previously described (Kiel I; Erlenkeuser, 1965). A few samples have been dated with a 3-L proportional counter. The copper counter is surrounded by 28 GM counters in the form of a double ring. The total assembly is shielded by 10 cm of old lead. Neither an inner lead shield between counter and anticoincidence ring nor screening of sensitive volume by a quartz tube-as in the 4.5-L counter-has been used. Background of the small counter is 17.20 cpm or The 0.95 x NBS value is 9.5 cpm at 400 torr. Within statistical error background does not depend on atmospheric pressure. The 3-L counter is placed under a concrete wall, 2.5 m in length and 9.4 m in height.

Hot Nodule

2009 ◽  
pp. 856-856
Author(s):  
Dieter Metze ◽  
Vanessa F. Cury ◽  
Ricardo S. Gomez ◽  
Luiz Marco ◽  
Dror Robinson ◽  
...  
Keyword(s):  
Hot Nodule

A PHANTOM STUDY SHOWING THE IMPORTANCE OF BREAST SHIELDING DURING HEAD CT

2020 ◽  
Vol 188 (4) ◽  
pp. 464-469 ◽  
Author(s):  
Nika Zalokar ◽  
Nejc Mekiš
Keyword(s):  
Computed Tomography ◽  
Dose Reduction ◽  
Phantom Study ◽  
Anthropomorphic Phantom ◽  
Head Ct ◽  
Lead Shield ◽  
Phantom Measurements ◽  
Lead Shielding ◽  
Head Computed Tomography

Abstract This study aimed to investigate the dose to the breasts during head computed tomography (CT) if lead shielding is used. The study was performed in two major hospitals using helical and axial protocols on an anthropomorphic phantom. Measurements were performed with and without the use of a lead shield of 0.5 mm equivalent density. The results showed a significant decrease in dose with the lead shielding in both hospitals. During the helical protocol, the use of shielding significantly reduced the dose by 96% in Hospital A and 82% in Hospital B. The dose reduction during axial protocol was also significant: 95% in Hospital A and 86% in Hospital B with lead shielding. Considering the significant dose reduction of 82% up to 96% during this study, we highly recommend the shielding of breasts regardless of the protocol used during head CT examinations.

Serum thyroid autoantibodies as a risk factor for development of hypopthyroidism after radioactive iodine therapy for single thyroid 'hot' nodule

1986 ◽  
Vol 113 (4) ◽  
pp. 500-507 ◽  
Author(s):  
Stefano Mariotti ◽  
Enio Martino ◽  
Marcello Francesconi ◽  
Claudia Ceccarelli ◽  
Lucia Grasso ◽  
...  
Keyword(s):  
Risk Factor ◽  
Life Table ◽  
Cumulative Incidence ◽  
Rare Complication ◽  
Serum Antibody ◽  
Significant Risk ◽  
Rank Test ◽  
Life Table Analysis ◽  
Hot Nodule ◽  
Table Analysis

Abstract. Hypothyroidism is often observed after radioiodine treatment in Graves' disease, but it is considered a rare complication in single hyperfunctioning thyroid nodule ('hot' nodule). This concept has been recently challenged, but the available data are conflicting. In the present study we therefore assessed the development of permanent hypothyroidism in 126 patients with thyroid hot nodule treated with 131I (180 μCi/g of estimated nodule weight, total dose 5.5–28.9 mCi). Follow-up ranged between 1 to 11 years. Hypothyroidism was observed in 5 (4%) patients, corresponding to a cumulative incidence by life-table analysis of 4.8% ten years after treatment. No relationship was found between the development of hypothyroidism and the size of the nodule or the total amount of administered dose. Fifty-six patients with euthyroid hot nodule at the time of treatment had higher cumulative incidence of hypothyroidism after 10 years (9.7%) than those with toxic adenoma (1.5%) (0.1 > P > 0.05 by logrank test). When the patients were analyzed according to the presence or absence of serum antithyroglobulin and/or antithyroid microsomal autoantibodies, the prevalence of hypothyroidism after 131I treatment was higher (4/25 = 16%) in patients with significant serum antibody titres (≥ 1/400 by pasive haemagglutination), when compared to that observed in subjects with negative antibody tests (1/101 = 1.0%). Life-table analysis showed in antibody positive patients a cumulative incidence of hypothyroidism after 10 years of 18.0% vs 1.4% in antibody negative patients (P <0.001 by log-rank test). In conclusion, the present data provide the first evidence that coexistent thyroid autoimmunity is a significant risk factor for the development of hypothyroidism in patients with hot nodule treated with radioiodine.

Sign in / Sign up

Export Citation Format

Share Document